Web2 aug. 2024 · AstraZeneca’s Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. 1. The approval by the Food and Drug Administration (FDA) was based on efficacy and safety data from the Saphnelo clinical development … Web1 dag geleden · Sarepta Therapeutics Inc. stock slid 6.4% Thursday, after a news report cast uncertainty over the path to regulatory approval for the company’s SRP-9001 gene therapy for a rare genetic disorder.
Pre-market development times for biologic versus small-molecule drugs …
WebNew Drug Therapy Approvals . 2024 . IMPAC T INNOVATION PREDICTABIL ITY ACCESS . FDA’s Center for Drug Evaluation and Research . January 2024. Table of … Web20 jan. 2024 · Two COVID-19 therapeutics were also granted approval – AstraZeneca PLC ’s Evusheld (tixagevimab/cilgavimab) and Pfizer Inc. ’s Paxlovid (nirmatrelvir/ritonavir). In 2024, seven COVID-19 products – four vaccines and three therapeutics – … earth drive iro
Ozempic Is About to Be Old News - The Atlantic
Web26 jan. 2024 · Among last year’s approvals were 31 new therapies for rare diseases. These new medicines include treatments for devastating neurodegenerative diseases such as spinal muscular atrophy and Duchenne muscular dystrophy, dangerous inflammatory conditions such as hereditary angioedema, and several rare and deadly forms of cancers. Web22 mrt. 2024 · 9/15/2024. To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations. 37. Skytrofa. … Web29 jan. 2024 · New formulations approved in 2024 included three different intravenous dosing regimens of atezolizumab, the first oral tablet combining decitabine plus cedazuridine, a subcutaneously injectable... earth drive dtu-1